LI Hui-ling, LIU Bi-qing, FENG Ying-nan, HU Xin, ZHANG Lan, DONG Xian-zhe. Research progress on strategies to target intestinal microbiota to improve drug resistance in tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2025, 60(2): 260-268. DOI: 10.16438/j.0513-4870.2024-0740
Citation: LI Hui-ling, LIU Bi-qing, FENG Ying-nan, HU Xin, ZHANG Lan, DONG Xian-zhe. Research progress on strategies to target intestinal microbiota to improve drug resistance in tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2025, 60(2): 260-268. DOI: 10.16438/j.0513-4870.2024-0740

Research progress on strategies to target intestinal microbiota to improve drug resistance in tumor immunotherapy

  • A growing body of research points out that gut microbiota plays a key role in tumor immunotherapy. By optimizing the composition of intestinal microbiota, it is possible to effectively improve immunotherapy resistance and enhance its therapeutic effect. This article comprehensively analyzes the mechanism of intestinal microbiota influencing tumor immunotherapy resistance, expounds the current strategies for targeted regulation of intestinal microbiota, such as traditional Chinese medicine and plant components, fecal microbiota transplantation, probiotics, prebiotics and dietary therapy, and explores the potential mechanisms of these strategies to improve patients' resistance to tumor immunotherapy. At the same time, the article also briefly discusses the prospects and challenges of targeting intestinal microbiota to improve tumor immunotherapy resistance, which provides a reference for related research to help the strategy research of reversing tumor immunotherapy resistance.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return